Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Relative Bioavailability and Food Effect Evaluation for 2 Tablet Formulations of Asciminib in a 2-Arm, Crossover, Randomized, Open-Label Study in Healthy Volunteers.

Menssen HD, Quinlan M, Kemp C, Tian X.

Clin Pharmacol Drug Dev. 2019 Apr;8(3):385-394. doi: 10.1002/cpdd.602. Epub 2018 Jul 30.

PMID:
30059193
2.

Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.

Menssen HD, Harnack U, Erben U, Neri D, Hirsch B, Dürkop H.

J Cancer Res Clin Oncol. 2018 Mar;144(3):499-507. doi: 10.1007/s00432-017-2564-6. Epub 2018 Jan 11.

PMID:
29327244
3.

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators.

N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.

4.

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.

Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gómez Casares MT, Hellmann A, Stentoft J, Conneally E, García-Gutiérrez V, Gattermann N, Wiktor-Jedrzejczak W, le Coutre PD, Martino B, Saussele S, Menssen HD, Deng W, Krunic N, Bedoucha V, Saglio G.

Leukemia. 2017 Jul;31(7):1525-1531. doi: 10.1038/leu.2017.63. Epub 2017 Feb 20.

5.

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.

Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM.

Leukemia. 2016 May;30(5):1044-54. doi: 10.1038/leu.2016.5. Epub 2016 Feb 3.

6.

Targeted ED-B fibronectin SPECT in vivo imaging in experimental atherosclerosis.

Dietrich T, Berndorff D, Heinrich T, Hucko T, Stepina E, Hauff P, Dinkelborg LM, Atrott K, Giovannoni L, Neri D, Fleck E, Graf K, Menssen HD.

Q J Nucl Med Mol Imaging. 2015 Jun;59(2):228-37.

PMID:
25864530
7.

Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.

Wang J, Shen ZX, Saglio G, Jin J, Huang H, Hu Y, Du X, Li J, Meng F, Zhu H, Hu J, Wang J, Hou M, Hertle S, Menssen HD, Ortmann CE, Tribouley C, Yuan Y, Baccarani M, Huang X.

Blood. 2015 Apr 30;125(18):2771-8. doi: 10.1182/blood-2014-09-601674. Epub 2015 Mar 12.

8.

The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.

Catania C, Maur M, Berardi R, Rocca A, Giacomo AM, Spitaleri G, Masini C, Pierantoni C, González-Iglesias R, Zigon G, Tasciotti A, Giovannoni L, Lovato V, Elia G, Menssen HD, Neri D, Cascinu S, Conte PF, Braud Fd.

Cell Adh Migr. 2015;9(1-2):14-21. doi: 10.4161/19336918.2014.983785.

9.

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.

Hughes TP, Hochhaus A, Kantarjian HM, Cervantes F, Guilhot F, Niederwieser D, le Coutre PD, Rosti G, Ossenkoppele G, Lobo C, Shibayama H, Fan X, Menssen HD, Kemp C, Larson RA, Saglio G.

Haematologica. 2014 Jul;99(7):1204-11. doi: 10.3324/haematol.2013.091272. Epub 2014 Feb 14.

10.

Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma.

Aloj L, D'Ambrosio L, Aurilio M, Morisco A, Frigeri F, Caraco' C, Di Gennaro F, Capobianco G, Giovannoni L, Menssen HD, Neri D, Pinto A, Lastoria S.

Eur J Nucl Med Mol Imaging. 2014 May;41(5):867-77. doi: 10.1007/s00259-013-2658-6. Epub 2014 Jan 17.

PMID:
24435772
11.

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.

Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, De Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A.

Blood. 2014 Feb 27;123(9):1353-60. doi: 10.1182/blood-2013-06-510396. Epub 2013 Dec 11.

12.

Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of (131)I-L19SIP in a prostate cancer patient.

Locher R, Erba PA, Hirsch B, Bombardieri E, Giovannoni L, Neri D, Dürkop H, Menssen HD.

J Cancer Res Clin Oncol. 2014 Jan;140(1):35-43. doi: 10.1007/s00432-013-1538-6. Epub 2013 Oct 17.

PMID:
24132461
13.

Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours.

Spitaleri G, Berardi R, Pierantoni C, De Pas T, Noberasco C, Libbra C, González-Iglesias R, Giovannoni L, Tasciotti A, Neri D, Menssen HD, de Braud F.

J Cancer Res Clin Oncol. 2013 Mar;139(3):447-55. doi: 10.1007/s00432-012-1327-7. Epub 2012 Nov 17.

PMID:
23160853
14.

Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma.

Papadia F, Basso V, Patuzzo R, Maurichi A, Di Florio A, Zardi L, Ventura E, González-Iglesias R, Lovato V, Giovannoni L, Tasciotti A, Neri D, Santinami M, Menssen HD, De Cian F.

J Surg Oncol. 2013 Feb;107(2):173-9. doi: 10.1002/jso.23168. Epub 2012 Jun 4.

PMID:
22674435
15.

Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies.

Erba PA, Sollini M, Orciuolo E, Traino C, Petrini M, Paganelli G, Bombardieri E, Grana C, Giovannoni L, Neri D, Menssen HD, Mariani G.

J Nucl Med. 2012 Jun;53(6):922-7. doi: 10.2967/jnumed.111.101006. Epub 2012 May 10.

16.

Local delivery of IL-2 reduces atherosclerosis via expansion of regulatory T cells.

Dietrich T, Hucko T, Schneemann C, Neumann M, Menrad A, Willuda J, Atrott K, Stibenz D, Fleck E, Graf K, Menssen HD.

Atherosclerosis. 2012 Feb;220(2):329-36. doi: 10.1016/j.atherosclerosis.2011.09.050. Epub 2011 Oct 5.

PMID:
22062588
17.

A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.

Eigentler TK, Weide B, de Braud F, Spitaleri G, Romanini A, Pflugfelder A, González-Iglesias R, Tasciotti A, Giovannoni L, Schwager K, Lovato V, Kaspar M, Trachsel E, Menssen HD, Neri D, Garbe C.

Clin Cancer Res. 2011 Dec 15;17(24):7732-42. doi: 10.1158/1078-0432.CCR-11-1203. Epub 2011 Oct 25.

18.

Microvascular biodistribution of L19-SIP in angiogenesis targeting strategies.

Czabanka M, Parmaksiz G, Bayerl SH, Nieminen M, Trachsel E, Menssen HD, Erber R, Neri D, Vajkoczy P.

Eur J Cancer. 2011 May;47(8):1276-84. doi: 10.1016/j.ejca.2011.02.001. Epub 2011 Mar 9.

PMID:
21396810
19.

The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma.

Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, Roemer A, Kloeters C, Rogalla P, Pecher G, Miller K, Berndt A, Kosmehl H, Trachsel E, Kaspar M, Lovato V, González-Iglesias R, Giovannoni L, Menssen HD, Neri D, de Braud F.

Eur J Cancer. 2010 Nov;46(16):2926-35. doi: 10.1016/j.ejca.2010.07.033. Epub 2010 Aug 24.

PMID:
20797845
20.

A review of the current evidence for maintenance therapy in ovarian cancer.

Foster T, Brown TM, Chang J, Menssen HD, Blieden MB, Herzog TJ.

Gynecol Oncol. 2009 Nov;115(2):290-301. doi: 10.1016/j.ygyno.2009.07.026. Epub 2009 Aug 31. Review.

PMID:
19717182
21.

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients.

Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, Hirsch B, Zardi L, Paganelli G, Mariani G, Neri D, Dürkop H, Menssen HD.

Blood. 2009 Mar 5;113(10):2265-74. doi: 10.1182/blood-2008-06-160416. Epub 2009 Jan 8.

22.

Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2.

Schliemann C, Palumbo A, Zuberbühler K, Villa A, Kaspar M, Trachsel E, Klapper W, Menssen HD, Neri D.

Blood. 2009 Mar 5;113(10):2275-83. doi: 10.1182/blood-2008-05-160747. Epub 2008 Nov 12.

23.

ED-B fibronectin as a target for antibody-based cancer treatments.

Menrad A, Menssen HD.

Expert Opin Ther Targets. 2005 Jun;9(3):491-500. Review.

PMID:
15948669
24.

Wilms' tumour gene 1 (WT1) in human neoplasia.

Keilholz U, Menssen HD, Gaiger A, Menke A, Oji Y, Oka Y, Scheibenbogen C, Stauss H, Thiel E, Sugiyama H.

Leukemia. 2005 Aug;19(8):1318-23.

PMID:
15920488
25.

Expression of Wilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants.

Siehl JM, Reinwald M, Heufelder K, Menssen HD, Keilholz U, Thiel E.

Ann Hematol. 2004 Dec;83(12):745-50. Epub 2004 Aug 31.

PMID:
15340762
26.

Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter study.

Pless M, Belhadj K, Menssen HD, Kern W, Coiffier B, Wolf J, Herrmann R, Thiel E, Bootle D, Sklenar I, Müller C, Choi L, Porter C, Capdeville R.

Clin Cancer Res. 2004 Feb 15;10(4):1299-305.

27.

Wilms tumor gene (WT1) expression as a panleukemic marker.

Menssen HD, Siehl JM, Thiel E.

Int J Hematol. 2002 Aug;76(2):103-9. Review.

PMID:
12215007
28.

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma.

Menssen HD, Sakalová A, Fontana A, Herrmann Z, Boewer C, Facon T, Lichinitser MR, Singer CR, Euller-Ziegler L, Wetterwald M, Fiere D, Hrubisko M, Thiel E, Delmas PD.

J Clin Oncol. 2002 May 1;20(9):2353-9.

PMID:
11981007
30.

The use of hirudin as universal anticoagulant in haematology, clinical chemistry and blood grouping.

Menssen HD, Melber K, Brandt N, Thiel E.

Clin Chem Lab Med. 2001 Dec;39(12):1267-77.

PMID:
11798089
31.

Measurement of hematological, clinical chemistry, and infection parameters from hirudinized blood collected in universal blood sampling tubes.

Menssen HD, Brandt N, Leben R, Müller F, Thiel E, Melber K.

Semin Thromb Hemost. 2001 Aug;27(4):349-56.

PMID:
11547357
32.

Cyclophosphamide, adriamycin and dexamethasone (CAD) is a highly effective therapy for patients with advanced multiple myeloma.

Szelényi H, Kreuser ED, Keilholz U, Menssen HD, Keitel-Wittig C, Siehl J, Knauf W, Thiel E.

Ann Oncol. 2001 Jan;12(1):105-8.

PMID:
11249035
33.

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.

Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J.

J Clin Oncol. 2001 Jan 15;19(2):558-67.

PMID:
11208851
34.

Primary tracheal leiomyosarcoma.

Reichert K, Helling K, Menssen HD, Perez-Canto A, Scherer H.

J Laryngol Otol. 2000 Jan;114(1):64-6.

PMID:
10789417
35.

Wilms' tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens.

Menssen HD, Bertelmann E, Bartelt S, Schmidt RA, Pecher G, Schramm K, Thiel E.

J Cancer Res Clin Oncol. 2000 Apr;126(4):226-32.

PMID:
10782896
36.
37.

Haemophagocytosis in bone marrow rhabdomyosarcoma.

Schwartz S, Menssen HD, Thiel E.

Br J Haematol. 1999 Jun;105(3):573. No abstract available.

PMID:
10354114
38.

Cryptococcosis in Hodgkin's disease: description of two cases and review of the literature.

Korfel A, Menssen HD, Schwartz S, Thiel E.

Ann Hematol. 1998 Jun;76(6):283-6. Review.

PMID:
9692818
39.

Distinction of eosinophilic leukaemia from idiopathic hypereosinophilic syndrome by analysis of Wilms' tumour gene expression.

Menssen HD, Renkl HJ, Rieder H, Bartelt S, Schmidt A, Notter M, Thiel E.

Br J Haematol. 1998 May;101(2):325-34.

PMID:
9609529
40.

Wilms' tumor gene expression in human CD34+ hematopoietic progenitors during fetal development and early clonogenic growth.

Menssen HD, Renkl HJ, Entezami M, Thiel E.

Blood. 1997 May 1;89(9):3486-7. No abstract available.

41.

Detection by monoclonal antibodies of the Wilms' tumor (WT1) nuclear protein in patients with acute leukemia.

Menssen HD, Renkl HJ, Rodeck U, Kari C, Schwartz S, Thiel E.

Int J Cancer. 1997 Mar 4;70(5):518-23.

42.

Xerocytosis with concomitant intrauterine ascites: first description and therapeutic approach.

Entezami M, Becker R, Menssen HD, Marcinkowski M, Versmold HT.

Blood. 1996 Jun 15;87(12):5392-3. No abstract available.

43.

Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias.

Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S, Reinhardt R, Thiel E.

Leukemia. 1995 Jun;9(6):1060-7.

PMID:
7596170
44.

Expression of the wt1 Wilms' tumor gene by normal and malignant human melanocytes.

Rodeck U, Bossler A, Kari C, Humphreys CW, Györfi T, Maurer J, Thiel E, Menssen HD.

Int J Cancer. 1994 Oct 1;59(1):78-82.

PMID:
7927908
45.

Growth regulation of cultured human nevus cells.

Mancianti ML, Györfi T, Shih IM, Valyi-Nagy I, Levengood G, Menssen HD, Halpern AC, Elder DE, Herlyn M.

J Invest Dermatol. 1993 Mar;100(3):281S-287S.

PMID:
8440904
46.

Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes.

Rodeck U, Melber K, Kath R, Menssen HD, Varello M, Atkinson B, Herlyn M.

J Invest Dermatol. 1991 Jul;97(1):20-6.

47.

Tumor progression in the human melanocytic system.

Kath R, Rodeck U, Menssen HD, Mancianti ML, Linnenbach AJ, Elder DE, Herlyn M.

Anticancer Res. 1989 Jul-Aug;9(4):865-72.

PMID:
2554787
48.

[Growth factors in the pathogenesis of malignant diseases].

Rodeck U, Menssen HD, Herlyn M.

Dtsch Med Wochenschr. 1988 Jun 3;113(22):904-6. Review. German. No abstract available.

PMID:
3286186
49.

Rapid dissociation of adherent human tumor cells by ultrasound.

Menssen HD, Herlyn M, Rodeck U, Koprowski H.

J Immunol Methods. 1987 Nov 23;104(1-2):1-6.

PMID:
3316390
50.

Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors.

Rodeck U, Herlyn M, Menssen HD, Furlanetto RW, Koprowsk H.

Int J Cancer. 1987 Nov 15;40(5):687-90.

PMID:
3316051

Supplemental Content

Loading ...
Support Center